Proactive Investors
27 Jun 2026, 08:42 UTC · 2h ago
SIRT6 gene therapy shows promise in aged dogs - ICYMI
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Proactive Investors
27 Jun 2026, 08:42 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
Genflow Biosciences will present results from its Age Dogs clinical trial evaluating centenarian SIRT6 gene therapy at the Animal Longevity Summit in October. — Clinical trial data presentations are primary value-drivers for pre-commercial biotech companies and can lead to significant price volatility.
+0.60Genflow is transitioning its delivery systems toward mRNA-LNP technology and is collaborating with Acuitas to transition its MASH programme. — Moving to non-viral delivery addresses AAV-related dosing challenges, potentially expanding the therapeutic window and commercial viability.
+0.40The company is currently maintaining confidential discussions with animal health companies regarding its trial data. — Ongoing partnership discussions suggest potential near-term licensing deals or commercial collaborations.
+0.30Which stocks this story touches
Continue reading
6 related stories
Search tags
Company is presenting clinical trial results at a major summit, which the CEO describes as important external validation of their data and methodology.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Proactive Investors
5h ago
